SENZIME

Scientific study presented at Euroanaesthesia 2023 validates new TetraGraph algorithm

The latest generation of Senzime's TetraGraph algorithm is shown to improve the detection of EMGs in 100% of cases, helping to better plan intraoperative drug dosing and facilitating patient safety.

Uppsala, June 5, 2023. Senzime AB (publ) today announced this weekend's scientific presentation at Euroanaesthesia 2023 in Glasgow, UK, validating the latest enhanced TetraGraph electromyographic (EMG) detection algorithm.

Euroanaesthesia 2023 is a yearly congress organized by the European Society of Anaesthesia and Intensive Care (ESAIC). The scientific poster presentation "Prospective evaluation of an enhanced electromyographic (EMG) detection algorithm" includes an evaluation of TetraGraph's latest EMG algorithm as compared to the previous generation for sensitivity and detection accuracy. The new EMG algorithm improves detection of EMGs in 100% of cases, without introducing false-positive EMGs. Improvements in EMG detection help better plan intraoperative drug dosing and optimal antagonism, decreasing residual paralysis and facilitating patient safety.

"The data presented in this scientific presentation solidify the place of TetraGraph as the market leader in perioperative neuromuscular monitoring. TetraGraph is an outstanding, easy-to-use, reliable and sensitive monitor; it should be the clinicians' ideal method for prevention of postoperative residual weakness and pulmonary complications," commented Sorin J. Brull, MD FCARCSI (Hon) Professor Emeritus of Anesthesiology and Perioperative Medicine, Mayo Clinic.

TetraGraph is a quantitative neuromuscular monitor, providing accurate monitoring of neuromuscular blockade during surgery. With the gold standard EMG technology, anesthesiologists can easily and accurately assess the patient's depth of paralysis, enabling confident decision making during all types of surgery and for any patient position.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at **senzime.com**.

Attachments

Scientific study presented at Euroanaesthesia 2023 validates new TetraGraph algorithm